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ARASITIC, bacterial, and viral infections and neoplastic 
disease profoundly affect host metabolism, disrupting 
normal homeostatic mechanisms both locally and sys- 
temically. A  large body of research has documented that 
many of  the observed biological responses to invasive stimuli 
are mediated by host-secreted cytokines, in particular, the se- 
cretory products of activated macrophages. One such cyto- 
kine, cachectin/tumor necrosis factor (TNF),~ has emerged 
as  a  particularly important mediator of inflammatory re- 
sponses. Among its pleiotropic effects,  cachectin/TNF has 
been shown to play a major endocrine role in the pathogene- 
sis of gram-negative endotoxic shock (14, 118) and to induce 
catabolic responses which could contribute to the profound 
wasting (cachexia) associated with many chronic diseases 
(24, 83, 104, 121). It has been implicated in a variety of dis- 
ease states including meningococcal septicemia (126), cere- 
bral malaria (43),  graft vs.  host disease (93),  and cancer 
cachexia (2, 8).  Systemic exposure to this potent mediator 
might elicit the pathologic and catabolic derangements as- 
sociated with such disease states. 
Cachectin/TNF has also been shown to exert local, tissue- 
specific effects. Its wide range of bioactivities includes stim- 
ulation of collagenase activity and prostaglandin E2 produc- 
tion by synovial cells (33), stimulation of osteoclast activity 
and bone resorption (9), promotion of angiogenesis (41, 60), 
and stimulation of procoagulant and platelet-activating factor 
activity in endothelial tissue (19, 75). It has also been shown 
to stimulate proliferation of normal fibroblasts (40, 114, 125), 
and to induce the release of certain growth factors including 
interleukin 1 (IL- 1), granulocyte-macrophage colony-stimu- 
lating factor (GM-CSF), I]2-interferon,  and platelet-derived 
growth factor (46, 55, 58, 73). The ability of cachectin/TNF 
to modulate such activities raises the intriguing possibility 
that it may play a paracrine role in the regulation of normal 
tissue homeostasis. 
Cachectin/TNF also exerts profound effects  on its own 
principal cell of origin, the macrophage. It serves as an auto- 
crine  immunomodulator, activating macrophages and en- 
hancing their cytotoxic potential in vitro (92).  It has been 
shown to be chemotactic for monocytes, suggesting that its 
production at a site of injury might function both to recruit 
additional macrophages and to activate those macrophages 
already present. 
1. Abbreviations  used in this paper:  IL-1, interleukin 1; LPL, lipoprotein 
lipase; LPS, lipopolysaccharide; TNF, tumor necrosis factor. 
The capacity of this potent cytokine to mediate the inflam- 
matory response, to modulate the metabolic activities of di- 
verse tissues, and to augment the function of other cytokines 
necessitates that its synthesis and release be closely con- 
trolled in vivo. Local production of cachectin/TNF at a site 
of injury might act to limit tissue damage and to promote 
wound healing and tissue remodeling.  Moderate systemic 
levels of the hormone might confer a survival advantage with 
respect to bacterial or viral infection by providing a useful 
mobilization of energy reserves for the acute metabolic de- 
mands of inflammatory responses. In sharp contrast to these 
beneficial effects, prolonged exposure to even low levels of 
cachectin/TNF might contribute to the cachexia associated 
with many chronic disease states.  Rapid uncontrolled pro- 
duction of cachectin/TNF, like that observed in response to 
endotoxemia or overwhelming gram-negative sepsis, could 
act systemically to induce the metabolic derangements of 
septic shock leading to cardiovascular collapse, acute organ 
failure, and death. 
History of Cachectin/TNF 
A  number of parasitic diseases including trypanosomiasis 
and leishmaniasis can profoundly alter host physiology lead- 
ing to severe wasting of the body (cachexia), and ultimately 
death of the host. Early studies by Rouzer and Cerami eluci- 
dated the underlying mechanisms involved in the cachexia 
associated with parasitic infection (98).  Rabbits chronically 
infected with Trypanosoma brucei brucei were observed to 
become anorectic and to undergo a life-threatening wasting 
of >50 % of their original lean body mass (98). Surprisingly, 
this wasting syndrome was observed in animals with only a 
low parasitic burden, and was associated with a marked lipe- 
mia (45,  98).  The elevated plasma triglyceride levels ob- 
served in infected animals were shown to result from sys- 
temic suppression of lipoprotein lipase, an enzyme which 
catalyzes the hydrolysis of lipoprotein-derived triacylglyc- 
erol, providing free fatty acids to the circulation for storage 
or catabolism (79, 108). A similar suppression of lipoprotein 
lipase (LPL) activity has also been observed in mice after 
treatment with endotoxin (100). Such observations led to the 
hypothesis that suppression of LPL activity and the onset of 
a lipolytic state were regulated by host factor(s) which were 
released in response to either parasitic or bacterial challenge. 
Taking advantage of  the availability of  two genetically similar 
strains of mice, one sensitive to lipopolysaccharide (LPS) 
(C3H/HeN)  and  the  other  resistant  to  LPS  (C3H/HeJ), 
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mained normal in LPS-resistant mice in response to LPS ad- 
ministration,  serum from LPS-treated LPS-sensitive mice, 
when transfused into LPS-resistant mice, acted to suppress 
LPL activity in those mice (53). Macrophages isolated from 
LPS-sensitive mice were shown to secrete a  factor in re- 
sponse to LPS stimulation in vitro which acted to suppress 
LPL activity in LPS-resistant mice. RAW 264.7,  a mouse 
macrophage cell line, secreted a factor with identical proper- 
ties when stimulated by LPS (11). Using the suppression of 
LPL activity in 3T3-L1 adipocytes as a bioassay, the factor 
responsible for the down-regulation of LPL activity in vivo 
in endotoxin-treated mice and in vitro in cultured adipocytes 
was isolated from LPS-stimulated RAW 264.7 cell superna- 
tants,  purified  to  homogeneity,  and  sequenced  (11). The 
purified protein, referred to as cachectin, had a subunit mo- 
lecular mass of 17 kD as determined by SDS-PAGE analysis. 
Its NH2-terminal amino acid sequence revealed a strong ho- 
mology to that of human TNF, a macrophage-derived poly- 
peptide hormone previously shown to cause hemorrhagic 
necrosis of certain tumors (10). With the observation of this 
striking  sequence homology between cachectin and TNE 
two disparate lines of research converged: the study of un- 
derlying mechanisms of cachexia and the study of mecha- 
nisms of endotoxin-induced necrosis of tumors. 
The historical background of TNF has been extensively 
reviewed elsewhere and will only be discussed briefly here 
(81, 82, 84). As early as the late 1800's,  the physician Wil- 
liam Coley had observed hemorrhagic necrosis of tumors in 
selected patients, those with concurrent bacterial infections 
of streptococcal or serratia origin. Subsequent work estab- 
lished that endotoxin, a  component isolated from the cell 
walls of gram-negative bacteria, was extremely effective at 
inducing  tumor  necrosis  (106).  In  1985,  Carswell  et  al. 
documented that a factor was present in the serum of BCG- 
primed,  endotoxin-treated  mice  that  was  able  to  induce 
hemorrhagic  necrosis  of a  mouse  sarcoma  and  complete 
regression of tumors in a proportion of treated animals (23). 
Macrophages were determined to be the principal source of 
this  factor (63,  66-68),  which  was  subsequently  isolated 
from supernatants of HL-60 promyelocytic leukemia cells 
stimulated with PMA (4). The factor was purified to homo- 
geneity  and  partially  sequenced  by  Aggarwal  et  al.  (4). 
Purified material induced necrosis of tumors in vivo and ex- 
erted cytostatic or cytocidal effects on certain tumor cell lines 
in vitro. A sensitive bioassay for TNF was developed based 
on its in vitro cytolytic action on actinomycin-D-treated mu- 
rine fibroblast L929 cells. 
A great deal of enthusiasm was generated with the hope 
that purification of TNF would enable clinicians to separate 
the beneficial antitumor properties of endotoxin treatment 
from its harmful effects, that of circulatory collapse, shock, 
and death.  When sequence analysis by Beutler et al.  con- 
firmed the identity of cachectin, the mediator of  cachexia and 
shock, with TNF, the mediator of tumor necrosis, it became 
apparent that scientists were dealing with a single pleiotropic 
mediator capable of eliciting a number of complex biological 
phenomena. 
Biosynthesis and Structure 
Cachectin/TNF has a subunit molecular mass of 17 kD and 
a pI of 3.9 (11). The physical properties of this molecule are 
quite similar irrespective of the species from which it is iso- 
lated (11, 47, 99). The amino acid sequence of murine, hu- 
man, and rabbit cachectin/TNF have now been determined 
from cDNA clones (39, 51, 64, 127). The mature mouse pro- 
tein is 156 residues long (39). The mature human protein is 
comprised of 157 residues due to the insertion of a histidine 
residue at position 73 (90), while the mature rabbit protein 
is only  154  residues  in length due to the absence of two 
NH2-terminal residues (52). 
In  all  three  mammalian  species  characterized to  date, 
cachectin/TNF is  synthesized as  a  prohormone, which  is 
subsequently cleaved at several discrete sites during process- 
ing to yield the mature 17-kD hormone (20, 39, 90). The un- 
cleaved precursor sequence is composed of 79 amino acids 
in the mouse, 76 in the human, and 80 in the rabbit (39, 51, 
90). The amino acid sequences of both the propeptide and 
the mature protein are highly conserved between mouse and 
human, with 79%  of the residues in the mature hormone, 
and 86% of the residues in the propeptide sequence being 
conserved between the two species (20, 39, 89). The fact that 
the propeptide sequence is so highly conserved suggests that 
it may possess a distinct biological function. It will be of in- 
terest to determine if the higher molecular mass prohormone 
species exhibit preferential tissue specificity or unique bio- 
logical functions, or if the clipped propeptides themselves 
are active in eliciting any biological activities distinct from 
those of either the uncleaved prohormone or the mature pro- 
tein. Isolated human monocytes do not secrete the same array 
of precursor species after stimulation by 7-interferon and 
LPS, but they do secrete three distinct proteins (20, 23, and 
25 kD), all three of which are recognized by polyclonal an- 
tisera  raised  against  human  recombinant  cachectin/TNF 
(85). 
Neither rabbit nor human cachectin/TNF contain poten- 
tial glycosylation sites (20,  52, 89). In contrast, the amino 
acid sequence of native murine cachectin/TNF contains one 
N-linked glycosylation site, an asparagine located at position 
7  (39).  Glycosylation of murine cachectin/TNF has been 
shown to include sialic acid and galactosamine (44). What 
role, if any, glycosylation  plays in the mechanism of  hormone 
action is still unclear as recombinant murine cachectin/TNF 
expressed in Escherichia coli, although not glycosylated, re- 
tains potent biological activity. 
All three species of cachectin/TNF sequenced to date con- 
rain two cysteine residues per subunit located at positions 69 
and 101 (4). Circular dichroism studies and secondary struc- 
ture prediction indicate that these two cysteine residues form 
an intrachain disulfide bridge on the surface of the molecule 
(4, 32). Reduction of the disulfide bridge has no detectable 
effect on either the secondary or the tertiary structure of the 
molecule (32). Studies involving cachectin/TNF analogues 
with substitutions at the two cysteine residues indicate that 
the disulfide bridge is not required for maintenance of either 
conformation or bioactivity of the molecule (74). 
Amino  acid  sequence  analysis  indicates  that  cachec- 
tin/TNF is  moderately hydrophobic (64).  Hydrophobicity 
plots of rabbit, mouse, and human cachectin/TNF indicate 
characteristic hydrophobic regions in both the prohormone 
and the mature protein, which are conserved among all three 
species (51, 64). Sequence data indicate that cachectin/TNF 
bears an unusual secretory protein signal sequence. It con- 
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nificantly longer than the typical signal sequence, and it con- 
tains a  variety of basic and acidic residues in the first 30 
amino acids (78,  90).  Recently, a  transmembrane form of 
cachectin/TNF has been characterized (56). This transmem- 
brane  form  is  rapidly  inducible  in  response  to  LPS  and 
PMA, and has been shown to be cytotoxic for L929 cells. It 
has been postulated that such a membrane-bound form of ca- 
chectin/TNF might allow for localization of  the action of this 
potentially lethal hormone. 
It has been reported that cachectin/TNF associates into di- 
meric, trimeric, or pentameric forms depending on the spe- 
cies from which it is isolated and the method of purification 
(4,  11, 44,  64,  107).  Recombinant human cachectin/TNF 
has been shown to associate into noncovalently linked tri- 
mers under conditions of both low and high salt (5). Recent 
cross-linking studies indicate that the trimer form is approxi- 
mately eightfold more active than the monomer with respect 
to receptor binding (109). 
Gene Expression and Regulation 
The cachectin/TNF gene is located on chromosome 6 in man 
(78, 112) and chromosome 17 in the mouse (72, 77). In both 
species it appears to be linked to the major histocompatibility 
complex (72,  112).  The human  cachectin/TNF gene has 
been linked to HLA-B and HLA-C on the one side and to the 
class III complement/steroid 21-hydroxylase gene cluster on 
the other using pulsed-field gel electrophoresis (22).  Up- 
stream from the cachectin/TNF gene lies the gene which 
codes for lymphotoxin, a related hormone which is produced 
by mitogen-stimulated lymphocytes and is thought to play a 
role in  lymphocyte-mediated killing  (31).  Cachectin/TNF 
and  lymphotoxin,  sometimes  referred  to  as  TNF~t  and 
TNFI~, respectively, share a 28% sequence homology (78), 
and have been shown to exhibit a number of shared biological 
activities including cytotoxicity for L929 cells and the ability 
to cause hemorrhagic necrosis of tumors in vivo (3). In addi- 
tion, these two molecules share' a common receptor. It has 
been postulated that both genes were derived from a com- 
mon ancestral gene by means of'a tandem duplication event. 
It is of interest to determine the cellular and tissue sources 
of  both molecules and to determine whether they are secreted 
in response to the same or distilact triggering mechanisms. 
The biosynthesis of cachectil~/TNF appears to be tightly 
regulated both at the transcriptional level and the posttran- 
scriptional level. Nuclear transcription assays indicate that 
cachectin/TNF gene transcription is enhanced some three- 
fold  in  macrophages  after stimulation  by endotoxin (12). 
Dexamethasone  was  found  to  suppress  this  endotoxin- 
induced increase in cachectin/TNF mRNA content (12). The 
transcription of the cachectin/TNF gene may also be under 
the control of short-lived repressor molecules which nor- 
mally serve to suppress its release (26).  A comprehensive 
study of the upstream region of the cachectin/TNF gene with 
respect to promoter and enhancer sequences has not yet been 
reported. Such a study would be revealing, especially with 
regard to any homology that might exist between the regula- 
tory  sequences  of cachectin/TNF and  the  regulatory  se- 
quences  of other mediators of the  host  inflammatory re- 
sponse. 
Posttranscriptional regulation of cachectin/TNF produc- 
tion involves in part the presence of a highly conserved AU- 
rich sequence located in the Y-untranslated region of  cachec- 
tin/TNF mRNA (20). This sequence is observed not only in 
cachectin/TNF mRNA, but also in the mRNA of a variety 
of inflammatory  mediators  including  lymphotoxin,  inter- 
feron, and interleukin-la and B, and more recently in the 
mRNA of certain oncogenes including c-myc and c-fos (20). 
It is thought to be a critical regulatory element controlling 
both the half-life of mRNA molecules and the efficiency with 
which they are translated (10, 20). This is supported by the 
fact that insertion of the AU-rich sequence of GM-CSF into 
the 3'-untranslated region of the globin gene seems to confer 
upon the resultant mRNA a significantly shortened half-life 
in  fibroblasts  (105).  Beutler et al.  have now  identified a 
nuclease present in the lysates of certain mammalian tissues, 
including  macrophages,  that  selectively degrades  mRNA 
molecules containing this Y-untranslated AU sequence (15). 
From model studies using synthetic mRNAs they conclude 
that the degree of message instability is dependent upon the 
number of copies of inserted AU sequence present in the tar- 
get mRNA molecule (15).  Tagging cachectin/TNF mRNA 
for rapid degradation may be one mechanism of controlling 
the effects of this potent hormone. 
Cachectin/TNF Receptor 
Most cell types including liver, kidney, muscle, and adipose 
tissue  have  been  shown  to  possess  specific  high  affinity 
receptors for cachectin/TNF (11), and the consequences of 
ligand binding appear to be tissue specific. Cachectin/TNF 
exhibits a high affinity for its receptor with a Ka estimated 
at  109 M -|  (7,  11,  48,  123).  Polyclonal antisera  raised in 
rabbits against peptides representing the NH2 terminus of 
human  recombinant  cachectin/TNF  have  been  shown  to 
block both receptor binding and bioactivity (111). Studies in- 
volving NH2-terminal deletion mutants of recombinant hu- 
man cachectin/TNF support the requirement for an intact 
NH2 terminus in receptor binding (21, 28).  Depending on 
cell type, several hundred to several thousand cell surface 
receptors for cachectin/TNF are available. Preincubation of 
cells with y-interferon significantly enhances the number of 
cell surface receptors for cachectin/TNF (3, 50). This phe- 
nomenon may be a  contributing factor to the synergy ob- 
served between these two cytokines (25, 40, 129). The recep- 
tor has not yet been isolated, and the nature of the signal 
transduced upon binding remains to be determined. A num- 
ber  of cross-linking  studies  with  radiolabeled  cachectin/ 
TNF ligand have indicated the existence of at least two poly- 
peptide chains of 75 and 90 kD that participate in binding 
(57,  103,  110, 122), and one recent study suggests that as 
many as four proteins may be involved (29). In vitro and in 
vivo studies  indicate that the biological effects of cachec- 
tin/TNF are maximally expressed at receptor occupancies as 
low as 5-10%. Binding of cachectin/TNF to its receptor is 
followed by rapid internalization (7) and degradation (123). 
Cachectin/TNF: Role in Endotoxic Shock 
During lethal endotoxemia a complex pattern of responses 
including metabolic acidosis, fever, hypotension, peripheral 
tissue lactate release, elevation of plasma catecholamines, 
disseminated intravascular coagulation, and renal, hepatic, 
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host.  Although originally attributed directly to endotoxin, 
it is now accepted that most, if not all, of these metabolic 
derangements are mediated by endogenous cytokines, and 
cachectin/TNF has been shown to play a major role. Signifi- 
cant quantities  of cachectin/TNF are  secreted by macro- 
phages after stimulation by LPS both in vivo and in vitro (1, 
13,  102).  In vivo studies have demonstrated that nanomolar 
levels of cachectin/TNF are present in the sera of mammals 
after administration of  lethal doses of endotoxin (13). Passive 
immunization of mice with polyclonal antibody to murine 
cachectin/TNF 6 h before the administration of otherwise le- 
thal doses of endotoxin conferred on them a significant sur- 
vival advantage (14). In a rabbit model of endotoxic shock, 
prior infusion of polyclonal antibody raised against human 
recombinant  cachectin/TNF  resulted  in  neutralization  of 
endotoxin-induced serum cachectin/TNF activity and pro- 
vided significant protection from the development of hypo- 
tension, histopathologic changes, and lethality (65). In vivo 
studies in mice, rats,  dogs, and humans have documented 
that many of the pathophysiologic changes observed after 
challenge with endotoxin can be reproduced by administra- 
tion of purified cachectin/TNF (13, 117, 120). In mice, the 
injection of recombinant cachectin/TNF induces piloerec- 
tion, diarrhea, fever, and eventual death (14). Infusion of hu- 
man recombinant cachectin/TNF into rats causes hypoten- 
sion, tachypnea, and death after respiratory arrest (117). As 
with endotoxin administration,  metabolic acidosis,  hemo- 
concentration and biphasic changes in blood glucose are ob- 
served (117). There is a significant accumulation of neutro- 
phils in the lungs, hemorrhagic necrosis of the adrenals and 
pancreas,  and  tubular  necrosis  in  the  kidney.  All  of the 
pathologic responses  noted above were prevented by pre- 
treatment of the rats with neutralizing murine monoclonal 
antibody against recombinant human cachectin/TNE 
Tracey et al. recently reported that passive immunization 
of  baboons with murine monoclonal antibody against recom- 
binant human cachectin/TNF protected them against the car- 
diovascular collapse and acute organ failure resulting from 
infusion of otherwise lethal quantities of live E.  coli (118). 
It is important to note that throughout the course of this study 
animals  passively  immunized  against  cachectin/TNF  ex- 
hibited a significant bacteremia indicating that the presence 
of bacteria  alone,  in  the  absence  of circulating  cachec- 
tin/TNF, is not sufficient to induce the full scope of metabol- 
ic derangements associated with sepsis (118). These findings 
document that in addition to being a principal mediator of 
endotoxic shock, cachectin/TNF is a critical mediator of le- 
thal bacterial sepsis. 
In  the  baboon  model  described  above,  peak  serum 
cachectin/TNF levels (20,500 +  9890 pg/ml) were observed 
90 min after the infusion of a lethal dose of live E.  coli.  A 
similar temporal pattern of cachectin/TNF release, an early 
burst followed by a rapid decline to undetectable levels, was 
observed when a bolus injection of endotoxin was given to 
human  volunteers  (49).  In  the  latter  study,  peak  serum 
cachectin/TNF  levels  (358  +  166 pg/ml)  were observed 
within 90 min of endotoxin challenge. These results indicate 
that cachectin/TNF is an early mediator of endotoxemia and 
bacteremia, and that although the magnitude is significantly 
different, the time course of cachectin/TNF appearance is 
similar in nonlethal and lethal models of acute sepsis. 
Cachectin/TNF: Role in Cachexia 
One  of the  original  motives  for studying  cachectin/TNF 
stemmed from the belief that it was involved in the severe 
wasting syndrome associated with chronic parasitic infection 
(11). Since then, the availability of recombinant material has 
allowed further characterization of the role cachectin/TNF 
plays in cachexia. Cachectin/TNF has been shown to induce 
a catabolic state in cultured 3T3-L1 adipocytes by suppress- 
ing key lipogenic enzymes including lipoprotein lipase, ace- 
tyl CoA carboxylase, and fatty acid synthetase (11, 87, 130); 
stimulating hormone sensitive lipase (86,  88); and increas- 
ing lactate production (86).  Torti et al.  demonstrated that 
cachectin/TNF inhibits adipo~te gene expression in TA 1 
adipocytes  inducing  an  in  vitro  "cachectic  state"  (116). 
Cachectin/TNF acts to prevent accumulation of lipid within 
differentiating preadipocytes and to cause mature lipid-laden 
adipocytes to lose stored triglycerides and to decrease adi- 
pose specific mRNAs by >90%  (116). By analogy one can 
envision an in vivo situation in which cachectin/TNF, while 
functioning to provide a necessary mobilization of  peripheral 
energy reserves for the acute metabolic demands of inflam- 
matory responses, may at the same time be contributing to 
the cachexia associated with many chronic disease states. 
Differentiated L6 myotubes respond to cachectin/TNF in 
a  similar catabolic manner,  with a  marked stimulation of 
glycogenolysis characterized by a rapid increase in fructose 
2,6-bisphosphate,  depletion of glycogen reserves,  and  in- 
creased production of lactate (59). These rapid changes are 
followed more slowly by increased synthesis of hexose trans- 
porters and concomitant stimulation of glucose uptake.  In 
vitro, isolated rat muscle fibers exhibit decreased membrane 
potential when incubated with low doses of cachectin/TNF 
(119). These decreases can be completely blocked by mono- 
clonal antibody specific for this hormone. In vivo, dogs in- 
fused with cachectin/TNF exhibit reduced resting hindlimb 
muscle transmembrane potentials and increased lactate re- 
lease (120). The latter study raises the possibility that the re- 
duced  resting  skeletal muscle membrane polarization ob- 
served in many critically ill patients (30) may result at least 
in  part  from  the  action  of this  mediator.  Recombinant 
cachectin/TNF does not appear to affect skeletal protein bal- 
ance, suggesting the involvement of other mediators as well 
(71). 
Recent in vivo studies using a rat model further support 
the role of cachectin/TNF in cachexia. Metabolic derange- 
ments typically associated with the cachexia of chronic dis- 
ease (including anorexia,  weight loss,  depletion of whole 
body protein and lipid stores, and anemia) were reproduced 
in rats given twice-daily sublethal injections of recombinant 
human cachectin/TNF for 8 d (121). In addition, daily injec- 
tions of anti-cachectin antibodies protected cachectin/TNF- 
treated animals against subsequent weight loss and anorexia 
(121). This study suggests that continual in vivo exposure to 
cachectin/TNF is  sufficient to  elicit many of the  clinical 
manifestations of cachexia. 
Additional support for the causative role of  cachectin/TNF 
in cachexia was obtained in experiments in which the cachec- 
tin/TNF  gene was  inserted into a  mammalian  expression 
vector and transfected into Chinese hamster ovary cells (83). 
When  these  cells,  which  continuously secrete  cachectin/ 
TNF both in vitro and in vivo, were implanted into the hind 
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chectin/TNF in the circulation. Mice treated in this manner 
developed a  wasting syndrome reminiscent of that seen in 
cancer cachexia.  In  sharp  contrast,  mice  implanted  with 
cells transfected with the expression vector alone continued 
to gain weight during the course of the experiment. 
Mice bearing a transplantable methylcholanthrene-induced 
sarcoma  become  cachectic,  exhibiting  significant  weight 
loss, hypoalbuminemia, and increased serum amyloid P con- 
centrations (62). Tumors recovered from these animals have 
been shown to spontaneously secrete cachectin/TNF in vitro 
(62). Studies are in progress to document to what extent in 
vivo production of cachectin/TNF in this model might con- 
tribute to the ensuing cachectic state. 
Tissue-specific Effects of Cachectin/TNF 
Endothelial Cells 
Cachectin/TNF  dramatically  alters  the  properties  of en- 
dothelial cells. In vitro, cachectin/TNF has been shown both 
to increase tissue factor procoagulant activity and to sup- 
press cofactor activity for the anticoagulant protein C path- 
way which normally acts to block clot formation within the 
vascular bed (75,  113).  The expression of thrombomodulin 
is also down-regulated (113).  These changes are dependent 
upon protein synthesis and favor procoagulant activity on the 
endothelial cell surface. In addition, cachectin/TNF stimu- 
lates endothelial cells to secrete IL-1 which has also been 
shown to enhance tissue  factor-like procoagulant activity 
(16, 18, 61, 76). The effects ofcachectin/TNF and IL-1 in this 
regard are additive (16, 17). The altered surface properties 
of endothelial cells observed in vitro in response to cachec- 
tin/TNF could play an important role in certain phenomena 
observed  in  vivo  after  infection  and  injury.  In  uncom- 
promised tissue the endothelial cell surface acts to control 
the  coagulation  of circulating  blood  and  to  restrict  the 
penetration of fluid, cells, and macromolecules into the tis- 
sues. One of the hallmarks of endotoxemia is disseminated 
intravascular coagulation with  increased capillary perme- 
ability and leakage of macromolecules into the tissue space. 
This could result from the interaction of cachectin/TNF and 
the vascular endothelium. The fact that activated protein C 
anticoagulant  activity  has  been  shown  to  protect  against 
coagulopathy and death  in bacteremic shock in a  baboon 
model  (115)  suggests that the ability of cachectin/TNF to 
suppress this activity is an important component of the toxic- 
ity observed after bacterial challenge. 
Cachectin/TNF also  stimulates  the  expression of endo- 
thelial cell surface antigens including ICAM  1 (95) and the 
surface antigens recognized by monoclonal antibodies H4/18 
and 60.1,  which function to modulate adherence of inflam- 
matory leucocytes to cultured endothelial ceils (42, 94-96). 
In addition to these effects on the endothelial cell surface, 
cachectin/TNF induces the synthesis of an endothelial cell 
surface factor(s) that promotes neutrophil adherence to the 
luminal surface of the vascular endothelium by a mechanism 
involving the neutrophil membrane adhesion complex CDwl 8 
(LFA-I/Mac-I/p150,95) (97). The expression of HLA-A and 
HLA-B on the surface of endothelial cells is also increased 
after exposure to  cachectin/TNF  (27).  The  adherence of 
blood cells to the endothelium is a critical factor in the devel- 
opment of an inflammatory state, and the ability of cachec- 
tin/TNF to modulate the expression of surface antigens that 
are involved in this process suggests that it may play a critical 
role. 
Bone, Cartilage, and Fibroblasts 
Inflammatory processes often lead to the destruction of host 
tissues. Cachectin/TNF has been implicated in a number of 
these processes including abscess formation and the resorp- 
tion of cartilage and bone observed in rheumatoid arthritis 
(9).  Cultured  human  synovial  cells  show  an  increased 
production of collagenase and prostaglandin E2 in response 
to cachectin/TNF (9). Collagenase can function to disrupt 
the extracellular collagen matrix in inflammed tissues, and 
PGE2 is thought to stimulate the production of intracellular 
proteases involved in tissue destruction and remodeling. Hu- 
man  recombinant  cachectin/TNF  causes  chondrocytes to 
both degrade proteoglycan through limited proteolysis and to 
inhibit the synthesis of new proteoglycan (101). The destruc- 
tion of proteoglycan, an essential component of the matrix 
of cartilage enabling tissue to resist compression during load 
bearing, results in severe impairment of the function of carti- 
lage. Cachectin/TNF also acts indirectly, stimulating fibro- 
blasts to produce IL-1, another mediator which is postulated 
to play an important role in the induction of proteolysis ob- 
served in inflammatory joint diseases (35).  The two cyto- 
kines may act in concert to bring about the tissue destruction 
observed in rheumatoid arthritis,  osteoarthritis,  and other 
joint diseases. 
Cachectin/TNF modulates the function of a broad range 
of normal fibroblasts. Dermal fibroblasts respond to cachec- 
tin/TNF with an increased production of collagenase and 
PGE2  (33).  Normal  lung  fibroblasts  show  an  enhanced 
production of prostaglandin in response to cachectin/TNF, 
and  this  response is augmented by  IL-1  (37).  Fibroblasts 
from several tissues have been shown to be growth stimulated 
by cachectin/TNF (40,  114,  125).  This proliferative effect 
can be explained at least in part by the ability of the mediator 
to stimulate fibroblasts to produce 132-interferon, a cytokine 
shown to function in an autocrine manner enhancing cell 
proliferation (55). The ability to stimulate fibroblast prolifer- 
ation may play a role in the repopulation and tissue remodel- 
ing which occurs after inflammation. This mediator has also 
been shown to induce an antiviral state in certain fibroblast 
cell lines (69). 
Leucocytes 
During sepsis and bacteremia marked changes are observed 
in both the number of circulating leucocytes, and in their 
state of activation. Cachectin/TNF has been shown to play 
an important role in these changes. It induces neutrophil de- 
granulation (54), and stimulates the release of reactive oxy- 
gen intermediates including superoxide anion (124) and hy- 
drogen peroxide (54). It also acts to increase the phagocytic 
capacity of treated neutrophils and to enhance their cytotox- 
icity to certain pathogens (36). This multifunctional media- 
tor has also been shown to be chemotactic for neutrophils 
(70). 
Cachectin/TNF acts in an autocrine fashion as well, ac- 
tivating macrophages and enhancing their cytotoxic potential 
in vitro (34, 92). It elicits an increase in the production of 
Sherry and Cerami Cachectin/TNF in Inflammatory Responses  1273 IL-1  and  PGE2  by  cultured  macrophages  (6).  Cachec- 
tin/TNF also induces the expression of the class II MHC an- 
tigen,  I-A,  on  the  surface  of macrophages.  It  synergizes 
strongly with interferon-y in this regard. In addition, cachec- 
tin/TNF is chemotactic for monocytes (70), and its produc- 
tion locally may serve to attract these cells, as well as neutro- 
phils,  to a site of injury. 
One of the hallmarks of the cellular response to tissue in- 
jury and sepsis is the recruitment and activation of both poly- 
morphonuclear leukocytes and macrophages. The ability of 
cachectin/TNF  to  activate  these  different  effector  mecha- 
nisms suggests that it may play a pivotal role in mounting a 
well-coordinated cellular response to infection and injury. 
Hepatic Tissue 
Cachectin/TNF has been shown to regulate the expression of 
acute phase proteins in vitro in human hepatoma cell lines 
through a  transcriptional mechanism  (91).  What role this 
may play in vivo is still unclear, although similar changes are 
observed  in vivo  in response  to inflammation  and  injury. 
Recombinant human cachectin/TNF has been shown to stim- 
ulate rat liver amino acid uptake fivefold in vivo (128), and 
to increase  responsiveness  to plasma  glucagon (128):  two 
metabolic alterations observed early in acute tissue injury or 
sepsis.  The  significance  of  these  findings  is  unclear  as 
cachectin/TNF has no direct effect on hepatocyte amino acid 
uptake in vitro (128) but does elevate hepatic lipogenesis in 
vivo (38). 
Conclusions 
Cachectin/TNF has been shown to be a pluripotent mediator 
influencing the  growth,  differentiation,  and  function of a 
broad range of cells and tissues. It has been shown to func- 
tion at many levels, exerting endocrine, paracrine, and auto- 
crine control of inflammatory responses. The various bioac- 
tivities  this  mediator  exhibits  in  vitro  and  in  vivo  lends 
support to the hypothesis that it plays an important role in 
both humoral and cell-mediated immune and inflammatory 
responses to injury and infection, and raises the possibility 
that it is involved in the regulation of normal tissue homeo- 
stasis. In addition to the direct actions of cachectin/TNF, its 
interaction with other host-secreted cytokines including IL-1, 
132-interferon,  y-interferon,  and  lymphotoxin  allows  it  to 
play an even more powerful role  in the regulation of cell 
growth and function. To try to harness the beneficial effects 
of cachectin/TNF  while controlling its adverse effects  is a 
daunting task, but one which if achieved, even to some de- 
gree,  would reap substantial rewards. 
Received  for publication 6  July  1988. 
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